Cover Image
市場調查報告書

嗜中性白血球低下症:開發中產品分析

Neutropenia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192734
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
嗜中性白血球低下症:開發中產品分析 Neutropenia - Pipeline Review, H2 2016
出版日期: 2016年09月28日 內容資訊: 英文 93 Pages
簡介

嗜中性白血球低下症,是負責擊退感染疾病的嗜中性白血球的數量異常少的狀態。徵兆與症狀有發熱、頻繁感染、口腔炎、齒齦感染疾病、排尿障礙等。

本報告提供嗜中性白血球低下症的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

嗜中性白血球低下症概要

治療藥的開發

  • 開發中產品的概要

嗜中性白血球低下症:企業開發中的治療藥

嗜中性白血球低下症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

嗜中性白血球低下症:企業開發中的產品

嗜中性白血球低下症的治療藥的開發企業

  • Apotex Inc.
  • Biogenomics Limited
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Limited
  • Ligand Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Prolong Pharmaceuticals, LLC
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH
  • Therapeutic Proteins International, LLC
  • 東光藥品工業
  • USV Limited

嗜中性白血球低下症:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

嗜中性白血球低下症:最近的開發平台趨勢

嗜中性白血球低下症:暫停中的計劃

嗜中性白血球低下症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8498IDB

Summary

Global Markets Direct's, 'Neutropenia - Pipeline Review, H2 2016', provides an overview of the Neutropenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neutropenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neutropenia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neutropenia
  • The report reviews pipeline therapeutics for Neutropenia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neutropenia therapeutics and enlists all their major and minor projects
  • The report assesses Neutropenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neutropenia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neutropenia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neutropenia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neutropenia Overview
  • Therapeutics Development
    • Pipeline Products for Neutropenia - Overview
  • Neutropenia - Therapeutics under Development by Companies
  • Neutropenia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Neutropenia - Products under Development by Companies
  • Neutropenia - Companies Involved in Therapeutics Development
    • Apotex Inc.
    • BeyondSpring Pharmaceuticals, Inc.
    • Biogenomics Limited
    • Cellerant Therapeutics, Inc.
    • Cleveland BioLabs, Inc.
    • Coherus BioSciences, Inc.
    • Dr. Reddy's Laboratories Limited
    • Eurofarma Laboratorios S.A.
    • Ligand Pharmaceuticals, Inc.
    • NAL Pharmaceuticals Ltd.
    • Prolong Pharmaceuticals, LLC
    • Richter Gedeon Nyrt.
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
    • Toko Pharmaceutical Industries Co., Ltd.
    • USV Pvt Ltd
  • Neutropenia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CAN-8337 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBLB-612 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LG-7455 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pegfilgrastim (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plinabulin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • romyelocel-L - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ST-7 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamibarotene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neutropenia - Dormant Projects
  • Neutropenia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (filgrastim) Patent Case
      • Sep 09, 2016: Apobiologix Announces Victory Over Amgen in Biosimilar (pegfilgrastim) Patent Case
      • Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study
      • May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication
      • Mar 31, 2016: Launch of Key Biosimilar Medicine To Help Save Healthcare Budgets
      • Feb 11, 2016: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim
      • Feb 01, 2016: Coherus Announces CHS-1701 (Neulasta Biosimilar) Met Both Primary Endpoints in Registration-Enabling Immunogenicity Study
      • Dec 21, 2015: Coherus BioSciences Signs Strategic Manufacturing Agreement With KBI Biopharma for Commercial Supply of CHS-1701
      • Dec 08, 2015: Coherus BioSciences Reports Update to CHS-1701 Program
      • Dec 08, 2015: EMA started the evaluation of Richter's marketing authorisation application for biosimilar pegfilgrastim
      • Dec 07, 2015: Phase III Data Shows Sandoz' Proposed Biosimilar Pegfilgrastim has Similar Safety and Efficacy as the Reference Product
      • Nov 18, 2015: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA
      • Oct 01, 2015: Coherus Announces Topline Results of CHS-1701 Pharmacokinetic and Pharmacodynamic Biosimilarity Study
      • Mar 17, 2015: Coherus Finalizes CHS-1701 BLA Enabling Clinical Program and Initiates Pivotal Pharmacokinetic and Pharmacodynamic Study
      • Feb 17, 2015: Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neutropenia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Neutropenia - Pipeline by Apotex Inc., H2 2016
  • Neutropenia - Pipeline by BeyondSpring Pharmaceuticals, Inc., H2 2016
  • Neutropenia - Pipeline by Biogenomics Limited, H2 2016
  • Neutropenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016
  • Neutropenia - Pipeline by Cleveland BioLabs, Inc., H2 2016
  • Neutropenia - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Neutropenia - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Neutropenia - Pipeline by Eurofarma Laboratorios S.A., H2 2016
  • Neutropenia - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
  • Neutropenia - Pipeline by NAL Pharmaceuticals Ltd., H2 2016
  • Neutropenia - Pipeline by Prolong Pharmaceuticals, LLC, H2 2016
  • Neutropenia - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Neutropenia - Pipeline by Sandoz International GmbH, H2 2016
  • Neutropenia - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Neutropenia - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016
  • Neutropenia - Pipeline by USV Pvt Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neutropenia - Dormant Projects, H2 2016
  • Neutropenia - Dormant Projects (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Neutropenia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top